Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7457637 | 0.88 | NPSR1 (0.50) | PTPN2PTPN1ABCC1NPC1METAP1 | |
| SCHEMBL2106155 | 0.86 | NPC1 (0.66) | MEN1KMT2ANPC1L3MBTL1LMNA | |
| SCHEMBL28881226 | 0.85 | METAP1 (0.48) | PTPN2PTPN1MEN1KMT2ANPC1 | |
| SCHEMBL7462727 | 0.85 | NPC1 (0.46) | PTPN2PTPN1ABCC1KMT2ANPC1 | |
| SCHEMBL5620033 | 0.84 | METAP1 (0.47) | ABCC1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1704198 | 0.83 | LMNA (0.51) | MEN1KMT2ANPC1RAB9AMETAP1 | |
| SCHEMBL9291119 | 0.82 | METAP1 (0.50) | MEN1KMT2ANPC1METAP1LMNA | |
| SCHEMBL15640149 | 0.81 | MAPK8 (0.58) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL14510093 | 0.81 | METAP1 (0.49) | NPC1METAP1LMNARXFP1HPGD | |
| SCHEMBL6242277 | 0.80 | METAP1 (0.46) | NPC1METAP1L3MBTL1LMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3558950-B1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-114213400-B | Thiophene-containing pyrimidine compound and preparation method and application thereof | 贵州大学 | 2022-11-08 | — | — | CN | disclosed |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | OLIGOMERIX, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-114213400-A | Thiophene-containing pyrimidine compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | disclosed |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. | 2019-11-14 | — | — | US | disclosed |
| CN-104822653-B | N-prop-2-ynylcarboxamide derivatives and their use as TRPA1 antagonists | 奥赖恩公司 | 2017-03-08 | — | — | CN | disclosed |
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| US-5869427-A | Substituted thiophene derivative and plant disease control agent comprising the same as active ingredient | MITSUI CHEMICALS, INC. (JP) | 1999-02-09 | — | — | US | disclosed |
| EP-0841336-A1 | Substituted thiopene derivative and plant disease control agent comprising the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-05-13 | — | — | EP | disclosed |
| EP-0609371-B1 | THIENOPYRAZINE-2,3-DIONES USEFUL FOR TREATING CNS DISORDERS, AND THEIR PREPARATION. | NOVO NORDISK AS (DK) | 1996-04-24 | — | — | EP | disclosed |
| EP-0609371-A1 | THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1994-08-10 | — | — | EP | disclosed |
| US-5284847-A | Neurological and psychological disorders; antagonist at the glycine binding site on the N-methyl-D-aspartate receptor complex | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| WO-1993008197-A1 | THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PTPN2 3095/4885PTPN1 2756/4885ABCC1 806/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | PTPN2 3141/4885PTPN1 2862/4885ABCC1 609/4885 |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | PTPN2 3278/4885PTPN1 3370/4885ABCC1 1527/4885 |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | MAPT, PSEN1, APP | PTPN2 3089/4885PTPN1 3100/4885ABCC1 1438/4885 |
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | PTPN2 3278/4885PTPN1 3370/4885ABCC1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.